MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Flex Pharma Company Profile (NASDAQ:FLKS)

Consensus Ratings for Flex Pharma (NASDAQ:FLKS) (?)
Ratings Breakdown: 5 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $27.20 (161.54% upside)

Analysts' Ratings History for Flex Pharma (NASDAQ:FLKS)
Show:
DateFirmActionRatingPrice TargetActions
6/10/2016Jefferies GroupReiterated RatingBuy$25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/3/2016HC WainwrightReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/2/2016Piper JaffrayReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/26/2016Cantor FitzgeraldReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/12/2016Roth CapitalLower Price Target$27.00 -> $24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/23/2015JMP SecuritiesInitiated CoverageOutperform$30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/27/2014 forward)
Earnings History for Flex Pharma (NASDAQ:FLKS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2016        
5/4/2016Q1($0.56)($0.61)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/8/2016Q415($0.56)($0.51)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2015Q315($0.44)($0.53)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2015Q215($0.37)($0.47)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2015Q1($0.29)($0.59)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/17/2015Q4($0.12)($1.82)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Flex Pharma (NASDAQ:FLKS)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.46)($0.46)($0.46)
Q2 20162($0.62)($0.52)($0.57)
Q3 20162($0.62)($0.55)($0.59)
Q4 20162($0.67)($0.61)($0.64)
(Data provided by Zacks Investment Research)
Dividend History for Flex Pharma (NASDAQ:FLKS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Flex Pharma (NASDAQ:FLKS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/23/2016Christoph H WestphalCEOBuy2,700$11.28$30,456.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/22/2016Christoph H WestphalCEOBuy5,700$11.05$62,985.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/21/2016Christoph H WestphalCEOBuy2,800$11.07$30,996.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/20/2016Christoph H WestphalCEOBuy6,000$11.18$67,080.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2016Christoph H WestphalCEOBuy5,800$11.17$64,786.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/14/2016Christoph H WestphalCEOBuy5,900$11.54$68,086.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2016Christoph H WestphalCEOBuy6,000$11.94$71,640.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2016Christoph H WestphalCEOBuy5,900$12.25$72,275.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/6/2016Christoph H WestphalCEOBuy6,000$12.56$75,360.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/2/2016Christoph H WestphalCEOBuy10,000$12.99$129,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/31/2016Christoph H WestphalCEOBuy22,300$12.68$282,764.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/26/2016Christoph H WestphalCEOBuy28,600$12.84$367,224.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/24/2016Christoph H WestphalCEOBuy30,334$12.42$376,748.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2016Christoph H WestphalCEOBuy7,914$11.06$87,528.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/18/2016Christoph H WestphalCEOBuy33,400$11.10$370,740.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2016Christoph H WestphalCEOBuy15,469$10.25$158,557.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/12/2016Christoph H WestphalCEOBuy30,217$10.12$305,796.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/10/2016Christoph H WestphalCEOBuy30,109$9.94$299,283.46View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/24/2016Christoph H WestphalCEOBuy49,563$11.06$548,166.78View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/22/2016Christoph H WestphalCEOBuy23,951$11.78$282,142.78View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/21/2016Christoph H WestphalCEOBuy48,058$11.74$564,200.92View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/18/2016Christoph H WestphalCEOBuy37,574$11.00$413,314.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/16/2016Christoph H WestphalCEOBuy38,379$10.23$392,617.17View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/15/2016Michelle StacyDirectorBuy2,585$9.63$24,893.55View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/14/2016Thomas WesselInsiderBuy20,000$7.94$158,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/11/2016Christoph H WestphalCEOBuy89,680$7.00$627,760.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/11/2016Roderick MackinnonDirectorBuy10,000$7.03$70,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/14/2015Christoph H WestphalCEOBuy927$12.01$11,133.27View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/7/2015Christoph H WestphalCEOBuy907$12.02$10,902.14View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2015Marc D KozinDirectorBuy4,500$11.38$51,210.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/16/2015Christoph H WestphalCEOBuy1,001$10.78$10,790.78View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/9/2015Christoph H WestphalCEOBuy1,000$11.03$11,030.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/26/2015Christoph H WestphalCEOBuy1,043$10.55$11,003.65View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/19/2015Christoph H WestphalCEOBuy1,018$10.61$10,800.98View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/28/2015Christoph H WestphalCEOBuy924$11.18$10,330.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/30/2015Christoph H WestphalCEOBuy272$20.52$5,581.44View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Flex Pharma (NASDAQ:FLKS)
DateHeadline
06/26/16 03:36 PMFlex Pharma Incorporated (NASDAQ:FLKS) Sellers Increased By 12.96% Their Shorts - Engelwood Daily
06/26/16 03:36 PMStrong Sell Calls Recommendations For Flex Pharma, Inc. (NASDAQ:FLKS) At 0 - Investor Newswire
06/23/16 04:28 AMFlex Pharma, Inc. (NasdaqGM:FLKS) Stock Momentum Hits Weakness - CML News
06/19/16 03:47 PMFlex Pharma, Inc. (FLKS) Analyst Price Targets For The Coming Week - Fiscal Standard
06/18/16 08:31 AMHere's What You Need To Know About The Flex Pharma Inc (NASDAQ:FLKS) MS Trial - Market Exclusive
06/17/16 03:51 PMHere’s What You Need To Know About The Flex Pharma Inc (NASDAQ:FLKS) MS Trial
06/15/16 04:05 PMFlex Pharma (FLKS) Commences FLX-787 Phase 2 in Australia as MS Treatment - StreetInsider.com
06/15/16 08:45 AMFlex Pharma (FLKS) Commences FLX-787 Phase 2 in Australia as MS Treatment
06/15/16 07:19 AMFlex Pharma Initiates Phase 2 Efficacy Study in Multiple Sclerosis - [at noodls] - -- FLX-787, A Single Molecule, Synthesized, TRP Ion Channel Activator, in Randomized, Controlled, Cross-over Study -- BOSTON--(BUSINESS WIRE)--Jun. 15, 2016-- Click to Tweet this News Flex Pharma, Inc. ...
06/06/16 01:26 PMFlex Pharma, Inc. :FLKS-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016 -
06/04/16 09:25 PMFlex Pharma's (FLKS) “Buy” Rating Reiterated at Cantor Fitzgerald - Let Me Know About This
06/03/16 10:13 PMFlex Pharma Inc (FLKS) Receives Buy Rating from Piper Jaffray - Let Me Know About This
06/03/16 04:16 PMStock Review and Earnings Check on Flex Pharma, Inc. (NASDAQ:FLKS) - HNN
06/03/16 04:16 PMHC Wainwright Reiterates Buy Rating for Flex Pharma Inc (FLKS) - Let Me Know About This
06/03/16 04:16 PMHC Wainwright Reiterates Buy Rating for Flex Pharma Inc (FLKS) - Let Me Know About This
06/03/16 07:25 AMFlex Pharma Presenting at Upcoming Investor Conferences in June 2016 - [at noodls] - BOSTON--(BUSINESS WIRE)--Jun. 3, 2016-- Click to Tweet Flex Pharma, Inc. (NASDAQ: FLKS) today announced that it will present a corporate overview at the following upcoming investor conferences in June: ...
06/03/16 06:41 AMFlex Pharma Launches First Consumer Product Scientifically Proven to Prevent and Treat Muscle Cramps - Business Wire (press release) - Flex Pharma Launches First Consumer Product Scientifically Proven to Prevent and Treat Muscle CrampsBusiness Wire (press release)Flex Pharma, Inc. (NASDAQ: FLKS), today announced that it has launched its cornerstone consumer product, HOTSHOT™, the first scientifically proven formula to prevent and treat muscle cramps, on its branded website www.TeamHOTSHOT.com.Broker Watchlist: Flex Pharma, Inc. (FLKS)Share Trading NewsFlex Pharma, Inc. (FLKS) Files Form 4 Insider Buying : Christoph H Westphal Buys 22300 SharesMarket DigestFlex Pharma Launches New Muscle Cramp Therapy HOTSHOT (NASDAQ:FLKS)Sonoran Weekly ReviewThe Post -Analyst Ratingsall 6 news articles »
06/02/16 04:12 PMFlex Pharma, Inc. (NASDAQ:FLKS) Stock Update & Estimates - Stock Tick Tock - Flex Pharma, Inc. (NASDAQ:FLKS) Stock Update & EstimatesStock Tick TockThe consensus on Wall Street is expecting Flex Pharma, Inc. (NASDAQ:FLKS) to post earnings of $-0.73 per share when the firm next reports it's fiscal quarterly results. According to the latest information available the report will likely be issued ...and more »
06/02/16 04:12 PMBroker Watchlist: Flex Pharma, Inc. (FLKS) - Share Trading News - Broker Watchlist: Flex Pharma, Inc. (FLKS)Share Trading NewsThey now have a USD 25 price target on the stock. 02/23/2015 – JMP Securities began new coverage on Flex Pharma, Inc. giving the company a “outperform” rating. The share price of Flex Pharma, Inc. (FLKS) was up +5.20% during the last trading session, ...Flex Pharma Launches First Consumer Product Scientifically Proven to Prevent and Treat Muscle CrampsBusiness Wire (press release)Flex Pharma, Inc. (FLKS) Files Form 4 Insider Buying : Christoph H Westphal Buys 22300 SharesMarket DigestTime to Buy Flex Pharma Inc After Today's Huge Increase?The PostAnalyst Ratings -Sonoran Weekly Reviewall 6 news articles »
06/02/16 07:00 AMScientific Breakthrough In Sports Nutrition To Change The Game For Millions Of Endurance Athletes - [PR Newswire] - BOSTON, June 2, 2016 /PRNewswire/ -- Exercise-associated muscle cramps are agonizing. Breakthrough research, to be presented today at the American College of Sports Medicine's Annual Meeting and published in the Journal of the American Medical Athletic Association later this month, has led to the development of a revolutionary new sports shot, HOTSHOT™, that is scientifically proven to prevent and treat muscle cramps by stopping them where they start: at the nerve. Invented by a Nobel Prize-winning neuroscientist and endurance athlete in collaboration with a Harvard Medical School neurobiology professor, HOTSHOT, previously codenamed #ITSTHENERVE, is a 1.7 fluid ounce sports shot comprised of a proprietary formula of GMO-free organic ingredients with a kick.
06/02/16 06:55 AMFlex Pharma Launches First Consumer Product Scientifically Proven to Prevent and Treat Muscle Cramps - [at noodls] - -- Harvard Medical School Professor, Dr. Bruce Bean, and Flex CMO, Dr. Tom Wessel, Presenting at American College of Sport Medicine Symposium -- BOSTON--(BUSINESS WIRE)--Jun. 2, 2016-- Flex Pharma, Inc. ...
06/01/16 04:16 PMTarget Price and Stock Performance Rundown for Flex Pharma, Inc. (NASDAQ:FLKS) - HNN - Target Price and Stock Performance Rundown for Flex Pharma, Inc. (NASDAQ:FLKS)HNNKeeping an eye on share activity using multiple views may be helpful when tracking stock performance. Equity investors have the ability to track short or long term share performance. During the latest trading session, Flex Pharma, Inc. (NASDAQ:FLKS ...and more »
06/01/16 04:16 PMInsiders Are Gradually Buying Flex Pharma, Inc. (NASDAQ:FLKS) - HNN - Insiders Are Gradually Buying Flex Pharma, Inc. (NASDAQ:FLKS)HNNAccording to the latest SEC filings, insiders at Flex Pharma, Inc. (NASDAQ:FLKS) have increased their position in the stock by 8.31% over the past 6 months. Insiders now own 39.60% of total outstanding shares. There are both legal and illegal types of ...and more »
05/30/16 10:42 PMFlex Pharma, Inc. (NASDAQ:FLKS) Boast 1-Year Price Target Of $27.6 - Investor Newswire - Flex Pharma, Inc. (NASDAQ:FLKS) Boast 1-Year Price Target Of $27.6Investor NewswireAs of 2016-05-29, Flex Pharma, Inc. (NASDAQ:FLKS) stock has an ABR of 1. This value was reached after accounting the price forecasts of 5 brokerages. The ABR mechanism encourages shareholders to invest in a stock which has a rating of '1'. Zacks has ...and more »
05/27/16 11:44 AMFlex Pharma Inc (NASDAQ:FLKS) Shares Approaching Top of Yearly Range - Small Cap Exclusive (press release) - Small Cap Exclusive (press release)Flex Pharma Inc (NASDAQ:FLKS) Shares Approaching Top of Yearly RangeSmall Cap Exclusive (press release)Flex Pharma Inc (NASDAQ:FLKS) is a biotechnology company that develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps. Its product candidates ...
05/26/16 10:48 AMFlex Pharma (FLKS) Commences Human Efficacy Study in NLC with TRP Activator - StreetInsider.com - Flex Pharma (FLKS) Commences Human Efficacy Study in NLC with TRP ActivatorStreetInsider.comFlex Pharma, Inc. (Nasdaq: FLKS) announced that it has initiated a human proof-of-concept efficacy study in nocturnal leg cramps (NLC) with its chemically synthesized, single molecule, transient receptor potential (TRP) ion channel activator ...Flex Pharma Shares Gain 4%; Starts Proof-of-Concept Study of Nocturnal Leg Cramps Tablet (NASDAQ:FLKS)Sonoran Weekly ReviewFlex Pharma Received its Third Buy in a RowAnalyst Ratings— CEOs Make Big Buys of Their Companies' StocksGuruFocus.comall 5 news articles »
05/25/16 07:16 AMFlex Pharma Initiates Human Efficacy Study with Single Molecule Tablet in Nocturnal Leg Cramps - [at noodls] - -- Single Molecule TRP Ion Channel Agonist in Randomized, Blinded, Controlled, Cross-over Study -- BOSTON--(BUSINESS WIRE)--May 25, 2016-- Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS) today ...
05/25/16 07:05 AM8:05 am Flex Pharma initiates a proof-of-concept efficacy study in nocturnal leg cramps with its transient receptor potential ion channel activator, formulated as an orally disintegrating tablet -
05/17/16 07:40 AMFLEX PHARMA, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
05/13/16 03:23 PMFLEX PHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Principal Of -
05/11/16 12:04 PMFLEX PHARMA, INC. Financials -
05/04/16 07:45 AMFlex Pharma Inc Earnings Call scheduled for 8:45 am ET today -
05/04/16 07:11 AMFLEX PHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition -
05/04/16 06:20 AMFlex Pharma Reports First Quarter 2016 Financial Results - [at noodls] - Flex Pharma Reports First Quarter 2016 Financial Results
05/04/16 06:16 AMFlex Pharma reports 1Q loss -
05/04/16 06:07 AMQ1 2016 Flex Pharma Inc Earnings Release - Before Market Open -
04/27/16 07:11 AMFlex Pharma to Report First Quarter 2016 Results on May 4, 2016 - [at noodls] - BOSTON--(BUSINESS WIRE)--Apr. 27, 2016-- Click to Tweet Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company developing innovative and proprietary treatments for nocturnal leg cramps (NLC), spasms ...
02/02/16 08:00 AMFlex Pharma, Inc. Announces Positive Human Efficacy in Nocturnal Leg Cramp Study - Call scheduled for 9:00 am ET today -
02/02/16 07:17 AMFLEX PHARMA, INC. Files SEC form 8-K, Other Events -
02/02/16 06:00 AMFlex Pharma Announces Positive Human Efficacy in Nocturnal Leg Cramp Study - [Business Wire] - Click to Tweet
01/14/16 10:25 AMFlex Pharma Announces FLX-787 as Clinical Drug Candidate - [at noodls] - -- MS, ALS and NLC Studies Expected to Initiate with Single Agent TRP Activator in 2016 -- -- Consumer Product to Prevent and Treat Cramps to Launch in the Second Quarter of 2016 -- BOSTON--(BUSINESS WIRE)--Nov. ...
01/14/16 10:25 AMFlex Pharma Presenting at Two Upcoming Healthcare Investor Conferences in November 2015 - [at noodls] - BOSTON--(BUSINESS WIRE)--Nov. 11, 2015-- Click to Tweet Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for nocturnal leg cramps and spasms ...
01/14/16 10:25 AMFlex Pharma Presenting at Two Upcoming Healthcare Investor Conferences in December 2015 - [at noodls] - BOSTON--(BUSINESS WIRE)--Nov. 23, 2015-- Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for nocturnal leg cramps and spasms associated ...
01/14/16 10:25 AMFlex Pharma Presents at the 26th International Symposium on ALS/MND - [at noodls] - -- Study in ALS Patients with FLX-787 Expected to Initiate First Half of 2016 -- BOSTON--(BUSINESS WIRE)--Dec. 9, 2015-- Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company ...
01/14/16 10:25 AMFlex Pharma Added to NASDAQ Biotechnology Index - [at noodls] - --(BUSINESS WIRE)--Dec. 21, 2015-- (NASDAQ: FLKS): Click to Tweet (NASDAQ: FLKS), a biotechnology company developing innovative and proprietary treatments for spasms associated with severe neuromuscular ...
01/14/16 10:25 AMEnrollment Completed in Flex Pharma’s Exploratory Human Nocturnal Leg Cramp Study - [at noodls] - -- Company Expects to Report Results Q1 2016 -- --(BUSINESS WIRE)--Jan. 6, 2016-- (NASDAQ: FLKS): Click to Tweet this News . (NASDAQ: FLKS), a biotechnology company developing innovative and proprietary ...
01/06/16 12:02 PMFlex Pharma Could Still Double From Here, Roth Analyst Says -
12/22/15 02:59 PMFLEX PHARMA, INC. Files SEC form 8-K/A, Change in Directors or Principal Officers -
12/22/15 07:40 AMFlex Pharma (FLKS) Looks Good: Stock Adds 5.9% in Session -
About Flex Pharma

Flex Pharma logoFlex Pharma, Inc. is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company's product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms. The Company operates through developing and commercializing products for nocturnal leg cramps, muscle cramps, spasms and spasticity associated with severe neuromuscular conditions, and exercise-associated muscle cramps segment. The Company's lead drug product candidate is FLX-787, which is in the Phase II clinical trial stage. It is developing a consumer brand and products specifically formulated to treat athletes suffering from EAMCs.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: FLKS
  • CUSIP:
Key Metrics:
  • Previous Close: $10.40
  • 50 Day Moving Average: $11.44
  • 200 Day Moving Average: $10.45
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $166.60M
  • Current Quarter EPS Consensus Estimate: $-2.59 EPS
Additional Links:
Flex Pharma (NASDAQ:FLKS) Chart for Monday, June, 27, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha